At the news
? BEARISHIMPACT 5/10 EFFECT filed Nov 13, 2026 at 00:15 ET
Fate Therapeutics' universal shelf registration (S-3, File No. 333-299862) became effective on November 12, 2026, enabling the company to sell up to $300M in securities including a $100M ATM facility. As a pre-revenue clinical-stage biotech with $139.1M cash and ongoing net losses, this effectiveness signals potential near-term dilution to fund pipeline development.
- Shelf registration (File No. 333-299862) became effective on November 12, 2026
- Shelf registers up to $300M in securities including a $100M ATM facility with Leerink Partners
- Company had $139.1M cash as of September 30, 2026
- Pre-revenue clinical-stage biotech with Q3 2026 net loss of $0.25 per share
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access